10x Genomics, Inc.

TXG

US88025U1097

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:00:00 2026-02-17 pm EST			5-day change	1st Jan Change
18.62 ^USD	+2.76%		-2.77%	+14.16%

Feb. 12	10x Genomics, Inc., Q4 2025 Earnings Call, Feb 12, 2026
Feb. 12	(TXG) 10x Genomics Expects 2026 Revenue Range $600M-$625M, vs. FactSet Est of $611.6M	MT

Cancer Research Institute launches transformative AI-driven immuno-oncology initiative powered by 10x Genomics technology

Published on 01/12/2026 at 09:09 am EST

Reuters

Latest news about 10x Genomics, Inc.

Feb. 12	10x Genomics, Inc., Q4 2025 Earnings Call, Feb 12, 2026
Feb. 12	(TXG) 10x Genomics Expects 2026 Revenue Range $600M-$625M, vs. FactSet Est of $611.6M	MT
Feb. 12	10x Genomics Q4 Loss Narrows, Revenue Rises; 2026 Guidance Set	MT
Feb. 12	Earnings Flash (TXG) 10x Genomics, Inc. Reports Q4 Revenue $166.0M, vs. FactSet Est of $159.7M	MT
Feb. 12	10X Genomics, Inc. Provides Earnings Guidance for the Full Year 2026	CI
Feb. 12	10x Genomics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
Feb. 04	PharosAI and 10x Genomics partner to transform cancer research with AI and spatial biology	RE
Feb. 04	Pharosai and 10X Genomics Partner to Transform Cancer Research with Ai and Spatial Biology	CI
Feb. 04	10x Genomics, PharosAI Enter Cancer Research Partnership	MT
Jan. 12	10x Genomics, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 08:15 AM
Jan. 12	Cancer Research Institute Launches Transformative Ai-Driven Immuno-Oncology Initiative Powered by 10X Genomics Technology	CI
Jan. 12	10X Genomics to Advance Research in Diagnostic Applications of Tumor Single Cell and Spatial Profiling	CI
Jan. 12	10X Genomics Launches Study to Advance Research in Blood-Based Diagnostics for Autoimmune Disease	CI
Jan. 12	10x Genomics Unveils Collaborations in Oncology, Blood-Based Diagnostics	MT
Jan. 12	Cancer Research Institute launches transformative AI-driven immuno-oncology initiative powered by 10x Genomics technology	RE

10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for analyzing biological systems. Its Chromium platform includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Chromium Single Cell Multiome ATAC + Gene Expression, Visium Spatial Gene Expression, and others.

Employees

1,178

Sector

Medical Equipment, Supplies & Distribution

Calendar

May. 05 - Q1 2026 Earnings Release (Projected)

More about the company